* 10X Genomics Inc reported a quarterly adjusted loss of 30 cents per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -79 cents. The mean expectation of nineteen analysts for the quarter was for a loss of 34 cents per share. Wall Street expected results to range from -57 cents to -27 cents per share.
* Revenue fell 1.3% to $151.65 million from a year ago; analysts expected $158.63 million.
* 10X Genomics Inc's reported EPS for the quarter was a loss of 30 cents.
* The company reported a quarterly loss of $35.75 million.
* 10X Genomics Inc shares had fallen by 29.8% this quarter and lost 71.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 8.2% in the last three months.
* In the last 30 days, five analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 9 "hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for 10X Genomics Inc is 22.50 This summary was machine generated from LSEG data October 30 at 02:49 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.34 -0.30 Beat
Jun. 30 2024 -0.48 -0.32 Beat
Mar. 31 2024 -0.50 -0.50 Met
Dec. 31 2023 -0.36 -0.41 Missed
Comments